Reviewed by Michael Gill, B. Sc.
14 Bydureon Clinical Trials Near Me
Top Cities for Bydureon Clinical Trials
Image of San Antonio in Texas.
San Antonio
3Active Trials
University Health System Texas Diabetic InstituteTop Active Site
Image of Toronto in Ontario.
Toronto
3Active Trials
Sunnybrook Health Sciences CentreTop Active Site
Most Recent Bydureon Clinical Trials

What Are Bydureon Clinical Trials?

Bydureon BCise is the brand name of a prolonged-release non-insulin medication, exenatide, designed to control blood sugar levels and keep them consistent. Bydureon treats type 2 diabetes mellitus, not type 1 diabetes.

This pre-filled, single-use injection pen medication is prescribed, in combination with diet and exercise, for adults, adolescents, and children ten years or older with type 2 diabetes that is inadequately controlled with just oral medications.

Bydureon clinical trials study the efficacy of Bydureon BCise for diseases that affect glucagon-like peptide-1 (GLP-1) receptors. This medication is approved for type 2 diabetes treatment but is also being evaluated for neurodegenerative disorders.

Why Is Bydureon BCise Being Studied In Clinical Trials?

Bydureon BCise is being studied to compare its effects in different patient populations and in combination with other drug or non-drug treatments. Researchers are testing the reduction of HbA1c (A1C) levels in clinical trial patients, especially patients ages 10-17.

Additional trials are exploring the efficacy of exenatide for Parkinson’s and Alzheimer’s Disease. GLP-1 receptors have been found in the brain, and studies are examining the neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders.

How Does Bydureon BCise Treatment Work?

Bydureon BCise uses an extended-release delivery system that works by stimulating GLP-1 receptors in the pancreas. It stimulates the pancreas to secrete insulin when blood sugar levels are high. It also slows gastric emptying from the stomach to send sugar into the bloodstream measuredly (see section 12 - Clinical Pharmacology).

Patients can self-inject this medication subcutaneously every seven days.

What Are Some of the Breakthrough Clinical Trials Involving Bydureon BCise?

Several recent studies have evaluated Bydureon BCise. Some of the most impactful studies are:

2017: Long-Term Efficacy for Type 2 Diabetes – This research evaluated studies and found that after 15 weeks of therapy, 2mg of exenatide achieved better glycemic control compared to a placebo and a lower dose of 0.8mg a week.

2020: Parkinson’s Disease – This research evaluated studies that compared GLP-1 receptor agonists with conventional Parkinson’s Disease (PD) treatment, placebo, or no treatment. The research found that exenatide may improve motor impairment for people with PD, though results have not been confirmed with high certainty.

2021: Adolescent Patients with Type 2 Diabetes – This study gave pediatric patients exenatide once weekly (EQW) as both monotherapy and adjunctive therapy to oral antidiabetic agents and insulin. The study found that exenatide extended-release significantly improved glycemic control compared to a placebo.

Who Are The Key Opinion Leaders On Bydureon Clinical Trial Research?

William Tamborlane, MD, is a professor of Pediatric Endocrinology at Yale University. He has conducted many studies on pediatric diabetes, including pioneering studies developing insulin pump therapy.

Stefano Genovese is the Director of the Diabetes, Endocrinology, and Metabolic Diseases unit at the Centro Cardiologico Monzino (IRCCS). He is an Italian researcher who has conducted significant research in medical fields surrounding diabetes. Genovese has studied diabetes and metabolism since 1991.

Dr. Richard Wyse is Director of Clinical Development at The Cure Parkinson’s Trust (CPT), a prominent research body for Parkinson’s Disease. He created the International Linked Clinical Trials programme (iLCT), which operates in the UK, US, Australia, and Europe.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: October 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Carreau AM, Pyle L, Garcia-Reyes Y, Rahat H, Vigers T, Jensen T, Scherzinger A, Nadeau KJ, Cree-Green M. Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). Clin Endocrinol (Oxf). 2019 Oct;91(4):544-552. doi: 10.1111/cen.14062. Epub 2019 Aug 16. https://pubmed.ncbi.nlm.nih.gov/313012512 Simon SL, McWhirter L, Diniz Behn C, Bubar KM, Kaar JL, Pyle L, Rahat H, Garcia-Reyes Y, Carreau AM, Wright KP, Nadeau KJ, Cree-Green M. Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3525-3534. doi: 10.1210/jc.2018-02385. https://pubmed.ncbi.nlm.nih.gov/308883983 Abdul-Ghani M, Puckett C, Adams J, Khattab A, Baskoy G, Cersosimo E, Triplitt C, DeFronzo RA. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care. 2021 Feb;44(2):433-439. doi: 10.2337/dc20-0978. Epub 2020 Dec 3. https://pubmed.ncbi.nlm.nih.gov/332730424 Skyler JS. Prevention and reversal of type 1 diabetes--past challenges and future opportunities. Diabetes Care. 2015 Jun;38(6):997-1007. doi: 10.2337/dc15-0349. https://pubmed.ncbi.nlm.nih.gov/259982925 Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011 Jan;60(1):1-8. doi: 10.2337/db10-1114. https://pubmed.ncbi.nlm.nih.gov/211937336 Alatrach M, Agyin C, Solis-Herrera C, Lavryneko O, Adams J, Gastaldelli A, Triplitt C, DeFronzo RA, Cersosimo E. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Diabetes Care. 2022 Jun 2;45(6):1372-1380. doi: 10.2337/dc21-1798. https://pubmed.ncbi.nlm.nih.gov/352356597 Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Res Care. 2021 Jun;9(1). pii: e002208. doi: 10.1136/bmjdrc-2021-002208. https://pubmed.ncbi.nlm.nih.gov/341724368 Luu QF, Villareal CJ, Fritschi C, Monson RS, Oberholzer J, Danielson KK. Concerns and hopes of patients with type 1 diabetes prior to islet cell transplantation: A content analysis. J Diabetes Complications. 2018 Jul;32(7):677-681. doi: 10.1016/j.jdiacomp.2018.04.002. Epub 2018 Apr 17. https://pubmed.ncbi.nlm.nih.gov/297798359 Koska J, Migrino RQ, Chan KC, Cooper-Cox K, Reaven PD. The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study. Diabetes Care. 2021 Jun;44(6):1385-1392. doi: 10.2337/dc20-2014. Epub 2021 Jan 25. https://pubmed.ncbi.nlm.nih.gov/33495294